What you should know:
1. Motus has $15.3 million in cash and investments.
2. In the quarter, Motus submitted a 510(k) application for the second-generation Pure-Vu System. The new system improves system mobility and setup logistics.
3. Motus has several milestones it anticipates hitting in the coming quarter, including:
- Announcing the full clinical results of its Reduce study at Digestive Disease Week 2019, May 18-21 in San Diego. In initially announced results, Pure-Vu showed a statistically significant improvement in bowel cleanliness from baseline in 45 patients.
- Starting investigator-led studies centering on Pure-Vu’s effectiveness for inpatient colonoscopy and high-risk outpatient colonoscopy populations
- Expanding its field-based sales and U.S. clinical resources market.
For more on Motus’ milestones, click here.
More articles on gastroenterology:
Where a Kansas ASC plans to invest for future growth: Q&A with Director Sonja Clapp
Orthopedist salaries, USPI revenue & more: 5 must-read articles for ASC administrators
5 key traits of effective ASC administrators
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
